Research Reports on Cervical Cancer from National Cancer Center Provide New Insights (The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naive primary stage IVB cervical cancer).

A recent study conducted at Asan Medical Center in Korea examined the efficacy and toxicity of paclitaxel-cisplatin-bevacizumab as a first-line treatment for platinum-naive primary stage IVB cervical cancer. The study included 61 patients with a median age of 56 years, who received a median of 9 cycles of treatment. The research found that a reduction rate of 40% in cervical mass size during treatment could be a potential prognostic factor for progression-free survival in these patients. The study concluded that paclitaxel-cisplatin-bevacizumab is effective and well-tolerated for this type of cancer. [Extracted from the article]